Efficacy and safety of lebrikizumab in moderate-to-severe atopic dermatitis: 52-week results of two randomized, double-blinded, placebo-controlled phase 3 trials (ADvocate1 and ADvocate2)

被引：0
|
作者：
Blauvelt, Andrew [1 ]
Thyssen, Jacob P. [2 ]
Guttman-Yassky, Emma [3 ]
Bieber, Thomas [4 ]
Carrascosa, Jose Manuel [5 ]
Simpson, Eric [6 ]
Rosmarin, David [7 ]
Elmaraghy, Hany [8 ]
Meskimen, Eric [8 ]
Natalie, Chitra R. [8 ]
Liu, Zhuqing [8 ]
Xu, Chenjia [8 ]
Pierce, Evangeline [8 ]
Morgan-Cox, MaryAnn [8 ]
Silverberg, Jonathan, I [9 ]
机构：
[1] Oregon Med Res Ctr, Portland, OR 97223 USA
[2] Univ Copenhagen, Bispebjerg Hosp, Copenhagen, Denmark
[3] Icahn Sch Med Mt Sinai, New York, NY USA
[4] Univ Hosp Bonn, Bonn, Germany
[5] UAB, Germans Trias i Pujol Univ Hosp, IGTP, Barcelona, Spain
[6] Oregon Hlth & Sci Univ, Portland, OR USA
[7] Tufts Univ, Sch Med, Boston, MA USA
[8] Eli Lilly & Co, Indianapolis, IN USA
[9] George Washington Univ, Sch Med & Hlth Sci, Washington, DC USA
来源：
BRITISH JOURNAL OF DERMATOLOGY | 2023年 / 188卷
关键词：
monotherapy; atopic dermatitis; moderate-to-severe; lebrikizumab; interleukin (IL)-13;
D O I：
10.1093/bjd/ljac140.018
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
322
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Rapid Improvement in Skin Pain Severity and Its Impact on Quality of Life in Adult Patients With Moderate-to-Severe Atopic Dermatitis From a Double-Blind, Placebo-Controlled Baricitinib Phase 3 Study
    Rosmarin, David
    Fretzin, Scott
    Strowd, Lindsay
    Casillas, Marta
    DeLozier, Amy M.
    Dawson, Zach
    Chen, Sherry
    Lu, Na
    Thyssen, Jacob P.
    JOURNAL OF CUTANEOUS MEDICINE AND SURGERY, 2022, 26 (04) : 377 - 385
  • [42] Efficacy and safety of upadacitinib vs dupliumab in adults and adolescents with moderate-to-severe atopic dermatitis: results of an open-label, efficacy assessor-blinded head-to-head phase 3b/4 study (Level Up)
    Silverberg, Jonathan, I
    Bunick, Christopher
    Hong, H. Chih-ho
    Mendes-Bastos, Pedro
    Gold, Linda Stein
    Costanzo, Antonio
    Ibrahim, Nadia
    Sancho, Cristina
    Wu, Xiaoqiang
    Han, Yu
    Levy, Gweneth
    Altman, Kathy
    Eyerich, Kilian
    BRITISH JOURNAL OF DERMATOLOGY, 2024, 191
  • [43] Efficacy and safety of topical OPA-15406, a new phosphodiesterase 4 inhibitor, in Japanese patients with atopic dermatitis for 8 weeks: A phase 2, randomized, double-blind, placebo-controlled study
    Saeki, Hidehisa
    Kawashima, Makoto
    Sugaya, Satoko
    Oshiden, Kazuhide
    Tsubouchi, Hidetsugu
    JOURNAL OF DERMATOLOGY, 2019, 46 (08) : 672 - 679
  • [44] A phase 3 randomized, multicenter, double-blind study to evaluate the safety of upadacitinib in combination with topical corticosteroids in adolescent and adult patients with moderate-to-severe atopic dermatitis in Japan (Rising Up) An interim 24-week analysis
    Katoh, Norito
    Ohya, Yukihiro
    Murota, Hiroyuki
    Ikeda, Masanori
    Hu, Xiaofei
    Ikeda, Kimitoshi
    Liu, John
    Sasaki, Takuya
    Chu, Alvina D.
    Teixeira, Henrique D.
    Saeki, Hidehisa
    JAAD INTERNATIONAL, 2022, 6 : 27 - 36
  • [45] Amlitelimab (an anti-OX40 ligand antibody) vs placebo in patients with moderate-to-severe atopic dermatitis: study design of phase 3 OCEANA clinical trials COAST 1/2, SHORE, AQUA, and ESTUARY
    Gold, Linda Stein
    Weidinger, Stephan
    Staumont-Salle, Delphine
    Nakajima, Saeko
    Simpson, Eric L.
    Weller, Marjolein de Bruin
    Davey, Sonya
    Rahawi, Kassim
    Bernigaud, Charlotte
    BRITISH JOURNAL OF DERMATOLOGY, 2024, 191 : 59 - 60
  • [46] Improvements in itch and sleep disturbance are maintained up to week 48 with nemolizumab plus TCS/TCI treatment in patients with moderate-to-severe atopic dermatitis: results from two global phase 3 pivotal studies (ARCADIA 1 and ARCADIA 2)
    Silverberg, Jonathan, I
    Wollenberg, Andreas
    Legat, Franz J.
    Laquer, Vivian T.
    Ulianov, Liliana
    Cheong, Soo Yeon
    Ryzhkova, Anna
    Piketty, Christophe
    BRITISH JOURNAL OF DERMATOLOGY, 2024, 191
  • [47] Efficacy and safety of roflumilast cream 0.15% in adults and children aged=6 years with mild to moderate atopic dermatitis in two phase 3 trials (INTEGUMENT-1 and INTEGUMENT-2)
    Simpson, Eric
    Eichenfield, Lawrence
    Gooderham, Melinda
    Gonzalez, Mercedes E.
    Hebert, Adelaide
    Papp, Kim
    Prajapati, Vimal
    Krupa, David
    Burnett, Patrick
    Berk, David
    Higham, Robert
    BRITISH JOURNAL OF DERMATOLOGY, 2023, 188
  • [48] A phase 2b, randomized, double-blind, multicenter, vehicle-controlled study to assess the efficacy and safety of two crisaborole regimens in Japanese patients aged 2 years and older with mild-to-moderate atopic dermatitis
    Fujita, Kayo
    Yagi, Michio
    Moriwaki, Shinichi
    Yoshida, Mizuki
    Graham, Daniela
    JOURNAL OF DERMATOLOGY, 2021, 48 (11) : 1640 - 1651
  • [49] Phase 2, randomized, double-blind, placebo-controlled, 4-week study to evaluate the safety and efficacy of OPA-15406 (difamilast), a new topical selective phosphodiesterase type-4 inhibitor, in Japanese pediatric patients aged 2-14 years with atopic dermatitis
    Saeki, Hidehisa
    Baba, Naoko
    Oshiden, Kazuhide
    Abe, Yuji
    Tsubouchi, Hidetsugu
    JOURNAL OF DERMATOLOGY, 2020, 47 (01) : 17 - 24
  • [50] Safety, Pharmacokinetics and Preliminary Efficacy of IL4-Rα Monoclonal Antibody AK120 in Both Healthy and Atopic Dermatitis Subjects: A Phase I, Randomized, Two-Part, Double-Blind, Placebo-Controlled, Dose-Escalation, First-In-Human Clinical Study
    Christopher John Wynne
    Alexandra Cole
    Charlotte Lemech
    Guoqin Wang
    Yu Zhang
    Benchao Chen
    Max Wang
    Baiyong Li
    Michelle Xia
    Rodney Sinclair
    Dermatology and Therapy, 2023, 13 : 2357 - 2373
12345